Abstract

Innovation Seminar Series Talk – online

“SMARTer health-tech” Dr Gita Khalili Moghaddam, CEO and founder of TumourVue and GlycoVue

About the Speaker Gita obtained her PhD in Biotechnology from the University of Cambridge in 2017. She is currently on secondment at GSK Global Health until 2023 as a UKRI Innovation Scholar, taking a leading role in the use of AI in tuberculosis drug development. Gita co-founded TumourVue Ltd in 2018 and GlycoVue Ltd in 2019.

In 2019, Gita was awarded a prestigious Borysiewicz Biomedical Sciences Fellowship at the University of Cambridge in recognition of her outstanding research in the field of biomedical engineering. As an academic entrepreneur, she has been widely recognised as one of the top 18 women in AI & Data by Innovate UK (2019), a BioBeat Mover & Shaker in BioBusiness (2020), top contender for Cofinitive 21toWatch (2021). Gita was recently awarded as “Business Woman of the Year” and as “Best New Business” with her venture GlycoVue by the SME Cambridgeshire Business Awards 2021.

About the Companies TumourVue is a disruptive imaging technology for cancer treatment. The delineation of tumour margins is challenging due to existing technical limitations. TumourVue’s innovative solution is a real-time imaging platform where AI creates a colour-coded image of precise tumour margins, superimposed on the surgeon’s eye during operation, to reduce the risk of local recurrence, improve survival rates and reduce treatment costs.

GlycoVue represents the accumulation of more than 15 years of experimental research in near-continuous glucose monitoring in readily accessible biological fluids. GlycoVue combines glucose-responsive smart polymers with advanced holography and AI-enabled smartphone-based instrumentation to create a platform for diabetes self-management. We have fabricated a transparent glucose-sensitive hologram using in-house synthesised boronate monomers as the selective glucose receptors. Preliminary in vitro assessment of its sensitivity, stability and performance appears promising. A smartphone is used to quantify the colour response of the hologram with an appropriate algorithm and convert it into the blood glucose concentration. Both ventures are spin-offs from the University of Cambridge.

Please register for the event here or send an email to ah930@cam.ac.uk